Here:The articles only open if you go to the link
Peter A McCullough, MD, MPH
Truth for Health Foundation - Cited by 66.584 - Internal Medicine - Cardiology - Nephrology
scholar.google.com
or more targeted, here:
Google Scholar
scholar.google.com
Peter A McCullough is a cardiologist and has authored or co-authored 100s of papers, mostly on the cardio-vascular system, kidney disease and surgical procedures. He's had dozens of papers of COVID effects on the heart and on red blood cells since 2020, and a handful on Ivermectin. All of his ivermectin research has suffered from incredibly small sample sizes, like this one with 26 cases: https://www.futuremedicine.com/doi/full/10.2217/fmb-2022-0014. It sincerely looks to me like McCullough is, for some reason, using the credibility and credentials built through decades of solid research on heart and circulatory system disease and treatment to signal boost some uncertain but maybe wort pursing further research on ivermectin and Covid.
So, instead of relying on a series of small sample size methodologically flawed studies, I'd suggest reading a review paper or a meta analysis paper. Meta-analyses essentially analyze the analyses and combine the findings to look for patterns across the series of small sample size studies. Here is one, for example, that finds:
Most RCTs had some concerns or high risk of bias, mostly due to lack of concealment of the randomization sequence and allocation, lack of blinding and high number of missing cases. Ivermectin did not show an effect in reducing mortality (RR = 0.76; 95%CI: 0.52–1.11) or mechanical ventilation (RR = 0.74; 95%CI: 0.48–1.16). This effect was consistent when comparing ivermectin vs. placebo, and ivermectin associated with SOC vs. SOC, as well as in sensitivity analysis.
Systematic review and meta-analysis of ivermectin for treatment of COVID-19: evidence beyond the hype - BMC Infectious Diseases
Background The role of ivermectin in the treatment of COVID-19 is still under debate, yet the drug has been widely used in some parts of the world, as shown by impressive market data. The available body of evidence may have changed over the last months, as studies have been retracted and...
bmcinfectdis.biomedcentral.com
It is important to seek a diversity of research on these kinds of emerging issues where sample sizes are difficult to accrue and haste leads to weakened statistical design.